GSK respiratory syncytial virus vaccine Phase 3 trial meets primary endpoint
[ad_1] GSK PLC said Thursday that a Phase 3 trial of its respiratory syncytial virus vaccine candidate for adults aged over 60 years met its primary endpoint. The U.K.-based maker…